CAR-T Therapy
CAR-T Therapy represents a revolutionary cellular immunotherapy approach genetically engineering patient T cells to express chimeric antigen receptors (CARs) that recognise tumour-associated antigens, redirecting immune responses to target and destroy cancer cells. This personalised treatment involves collecting T cells from patients through leukapheresis, genetically modifying them using viral vectors to introduce CAR genes encoding synthetic receptors combining antibody-derived binding domains with T-cell activation signals, expanding modified cells ex vivo, and infusing them back into patients where they proliferate and exert anti-tumour activity. CAR-T therapies have achieved remarkable success in treating refractory haematological malignancies, with some patients experiencing durable remissions after single infusions.
The biopharmaceutical industry has rapidly advanced CAR-T technology from academic concepts to approved commercial therapies, with robust pipelines targeting additional cancers and refining approaches. Manufacturing presents unique challenges as each product represents an individualised medicine requiring specialised facilities, complex supply chains coordinating patient material collection and product delivery, stringent quality controls for living cellular products, and cryopreservation systems maintaining cell viability during distribution. Clinical management requires specialised expertise recognising and treating CAR-T-associated toxicities including cytokine release syndrome and neurotoxicity. Companies developing CAR-T platforms invest in novel CAR designs enhancing tumour targeting specificity, incorporating safety switches enabling treatment termination if necessary, and engineering receptors targeting solid tumours. Allogeneic or 'off-the-shelf' CAR-T approaches using donor cells promise reduced costs and immediate availability compared to autologous personalised manufacturing. As technology matures through improved manufacturing efficiency, combination approaches, and expanded target repertoires, CAR-T therapy continues transforming oncology treatment paradigms.